Increased transcriptional levels of SOX10 are suggested to desensitize BRAF‐mutant melanoma to MAPK inhibition, however, loss of SOX10 has also been shown to drive acquired resistance.2, 11. The gene discussed is SOX10; the disease is melanoma.